Intervention Review

You have full text access to this OnlineOpen article

Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults

  1. Mattias Linde1,*,
  2. Wim M Mulleners2,
  3. Edward P Chronicle3,
  4. Douglas C McCrory4,5

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 24 JUN 2013

Assessed as up-to-date: 15 JAN 2013

DOI: 10.1002/14651858.CD010611

How to Cite

Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD010611. DOI: 10.1002/14651858.CD010611.

Author Information

  1. 1

    Norwegian University of Science and Technology, Department of Neuroscience, Trondheim, Norway

  2. 2

    Canisius Wilhelmina Ziekenhuis, Department of Neurology, Nijmegen, Netherlands

  3. 3

    University of Hawaii at Manoa, (Deceased) Department of Psychology, Manoa, USA

  4. 4

    Duke University Medical Center, Department of Medicine, Durham, NC, USA

  5. 5

    Durham Veterans Affairs Medical Center, Center for Health Services Research in Primary Care, Durham, NC, USA

*Mattias Linde, Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway. mattias.linde@ntnu.no.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 24 JUN 2013

SEARCH

[Figure 1]
Figure 1. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Divalproex sodium versus placebo, Outcome 1 ORs for responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Divalproex sodium versus placebo, Outcome 2 RRs for responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 2.1]
Analysis 2.1. Comparison 2 Sodium valproate versus placebo, Outcome 1 Headache frequency (post-treatment).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Sodium valproate versus placebo, Outcome 2 ORs for responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Sodium valproate versus placebo, Outcome 3 RRs for responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 3.1]
Analysis 3.1. Comparison 3 Sodium valproate dose comparisons, Outcome 1 Headache frequency (post-treatment).
[Analysis 4.1]
Analysis 4.1. Comparison 4 Sodium valproate versus flunarizine, Outcome 1 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 5.1]
Analysis 5.1. Comparison 5 Divalproex sodium versus propanolol, Outcome 1 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 6.1]
Analysis 6.1. Comparison 6 Sodium valproate versus topiramate, Outcome 1 Headache frequency (post-treatment).
[Analysis 6.2]
Analysis 6.2. Comparison 6 Sodium valproate versus topiramate, Outcome 2 MIDAS score.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Safety of sodium valproate and divalproex sodium versus placebo, Outcome 1 Any adverse event.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Safety of sodium valproate and divalproex sodium versus placebo, Outcome 2 Asthenia/fatigue.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Safety of sodium valproate and divalproex sodium versus placebo, Outcome 3 Dizziness/vertigo.
[Analysis 7.4]
Analysis 7.4. Comparison 7 Safety of sodium valproate and divalproex sodium versus placebo, Outcome 4 Nausea.
[Analysis 7.5]
Analysis 7.5. Comparison 7 Safety of sodium valproate and divalproex sodium versus placebo, Outcome 5 Tremor.
[Analysis 7.6]
Analysis 7.6. Comparison 7 Safety of sodium valproate and divalproex sodium versus placebo, Outcome 6 Weight gain.